GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

Active filtersClassification:Core

Showing 37-48 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trial.

Yen FS; Liao PL; Hung YM; Hsu CC; Liu CS; Hou MC; Hwu CM; Wei JC

2026PubMedDirectly related

Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.

Puspitasari IM; Putra DS; Deliyana AN; Adiputri NI; Octovia LI; Paramita SA; Sinuraya RK

Jan 1, 2026Diabetes, metabolic syndrome and obesity : targets and therapy

2026PubMedDirectly related

GLP-1 Receptor Agonists in Diabetic Lower Extremity Peripheral Artery Disease: From Mechanisms to Clinical Practice.

Pan J; Guo C; Huang Q; Zhang Y; Shen Y; Guo C

Jan 1, 2026British journal of hospital medicine (London, England : 2005)

2026PubMedDirectly related

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.

Pedagogos E; Chen R; Nelson A; Badve S; Rasalam R; MacIsaac R

Jan 1, 2026Internal medicine journal

2026PubMedDirectly related

Global Landscape and Thematic Evolution of Selective GLP-1 Receptor Agonists and GLP-1-Based Multi-Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis.

Wang Y; Liu Z; Wang S; Lv C; El-Seedi HR; Khalifa SAM; Wang H

Jan 1, 2026Endocrinology, diabetes & metabolism

2026PubMedDirectly related

Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.

Orandi BJ; Yan L; Levan ML; Lofton HF; Chhabra KR; Ren-Fielding CJ; Husain SA; McAdams-DeMarco MA; Segev DL; Mankowski MA; Massie AB

Jan 1, 2026Obesity (Silver Spring, Md.)

2026PubMedDirectly related

Case Report: Acute biliary pancreatitis after semaglutide dose escalation in an adolescent with obesity and cholelithiasis.

Alanizi AH; Alruwythi GM; Alotaibi NH; Alanazi NH; Alghurabi AM; Qubaiban R; Alsubaie N

Jan 1, 2026Frontiers in pediatrics

2026PubMedDirectly related

GLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review.

Malluhi M; Al-Naemi A; Akhtar S

Jan 1, 2026Biomolecules & biomedicine

2026PubMedDirectly related

Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.

Mehetre KN; Dawane JS

Jan 1, 2026Frontiers in endocrinology

2026PubMedDirectly related

Neuropsychiatric Outcomes Associated with GLP-1 Receptor Agonists in Adults with Overweight or Obesity: A Systematic Review.

Lubo C; Bustamante R; Quintana L; Guillen-Burgos HF

Jan 1, 2026Brain sciences

2026PubMedDirectly related

Hypothalamic obesity in pediatric vs. adult craniopharyngioma: mechanisms, management, and cardiometabolic outcomes.

Gupta K; Zeinali M; Altschul D; Agarwal V; Karsy M

Jan 1, 2026Pituitary

2026PubMedDirectly related

GLP-1 Receptor Agonists as Molecular Relievers of Lipotoxic Stress: From Pancreatic Beta-Cell Cholesterol Efflux to Systemic and Tissue-Specific Metabolic Protection.

Jiang W; Fukunaga K; Kobayashi T; Saheki T; Yoshimura T; Zhang H; Ly R; Imachi H; Murao K

Jan 1, 2026International journal of molecular sciences